July 13, 2000
Canadian Company prepared to provide low cost AIDS treatment within months
TORONTO, ONTARIO, CANADA – Canadian generic pharmaceutical manufacturer Apotex Inc. said today that it can have low cost alternatives to the major AIDS treatments available for developing countries within months if the Canadian Federal Government will grant it the needed compulsory licenses under the Patent Act...

April 10, 2000
European Court Rejects Olivieri's Bid to Annul the approval of Life Saving Drug
TORONTO, ONTARIO, CANADA – The Court of First Instance of the European Union released its ruling regarding Dr. Nancy Olivieri’s challenge of the European Commission and rejected her bid to have the approval of FerriproxÔ annulled. FerriproxÔ is the only alternative for the treatment of iron overload, and it has been approved for patients unable to take, DesferalÔ ...

March 14, 2000
Launch of Life Saving Drug in Europe to assist those patients Facing Possible Death
TORONTO, ONTARIO, CANADA – Apotex Inc. announced today the official launch of Ferriproxä in Europe. Ferriproxä; is the first medicine approved for the treatment of iron overload, since the approval of Desferal^® more than 30 years ago. The major advantage of Ferriproxä; is that this iron chelator can be taken by mouth instead of by daily injections, over an 8-12 hour period, 5-7 times a week required for Desferal^®...

January 19, 2000
Lovastatin Injunction Against Novopharm
WINNIPEG, MANITOBA, CANADA – The Manitoba Court of Queen’s Bench extends injunction against Novopharm prohibiting any work on the drugs Lovastatin, Simvastatin, Pravastatin and Compactin to January 18, 2001. In a decision released yesterday, the Honourable Mr. Justice Michel Monnin granted Apotex an extension to an injunction he had granted earlier after a lengthy trial.